| |
Patients
|
Endometrial cancer mortality
|
|---|
| |
N
|
Deaths
|
HR
|
95% CI
|
|---|
|
Age at diagnosis of endometrial cancera
|
|
< 55
|
190
|
14
|
1.00
|
baseline
|
|
55 to 64
|
469
|
51
|
1.57
|
0.87, 2.84
|
|
65 to 74
|
653
|
87
|
2.13
|
1.21, 3.75
|
|
75 to 84
|
445
|
92
|
3.65
|
2.08, 6.43
|
|
85 and over
|
118
|
33
|
5.69
|
3.03, 10.7
|
|
Heterogeneity (4 d.f.)
| | |
P < 0.0001
|
|
Trend (1 d.f.)
| | |
P < 0.0001
|
|
FIGO stageb
|
|
I
|
1016
|
64
|
1.00
|
baseline
|
|
II
|
132
|
26
|
3.34
|
2.11, 5.28
|
|
III/IV
|
140
|
67
|
13.1
|
9.25, 18.6
|
|
Unknown
|
587
|
120
|
2.92
|
2.06, 4.14
|
|
Heterogeneity (3 d.f.)
| | |
P < 0.0001
|
|
Morphologyc
|
|
Endometrioidd
|
1580
|
162
|
1.00
|
baseline
|
|
Serous or clear celle
|
108
|
32
|
2.25
|
1.51, 3.37
|
|
Carcinosarcomaf
|
108
|
54
|
5.41
|
3.92, 7.45
|
|
Sarcomag
|
54
|
20
|
3.93
|
2.42, 6.38
|
|
Unknown
|
25
|
9
|
4.11
|
2.06, 8.14
|
|
Heterogeneity (4 d.f.)
| | |
P < 0.0001
|
|
All non-endometrioidh
|
270
|
106
|
3.75
|
2.88, 4.87
|
|
Morphology by tamoxifen usec
|
|
Tamoxifen users:
| | | | |
|
- non-endometrioid
|
190
|
79
|
3.32
|
2.06, 5.35
|
|
-endometrioid
|
929
|
105
|
1.00
|
baseline
|
|
Tamoxifen non-user
| | | | |
|
- non-endometrioid
|
80
|
27
|
3.88
|
2.86, 5.28
|
|
-endometrioid
|
651
|
57
|
1.00
|
baseline
|
|
Heterogeneity interactionh (1 d.f.)
| | |
P = 0.57
|
|
Morphology unknown:
|
25
|
9
| | |
- aAdjusted for time since diagnosis of endometrial cancer, study, calendar period, FIGO stage;
- badjusted for time since diagnosis of endometrial cancer, study, calendar period, attained age;
- cadjusted for time since diagnosis of endometrial cancer, study, calendar period, FIGO stage, attained age;
- d endometrial adenocarcinoma, mixed cell adenocarcinoma, papillary endometrial adenocarcinoma;
- eserous adenocarcinoma, clear cell adenocarcinoma; fcarcinosarcoma, Mullerian mesodermal mixed tumors; gsarcoma, endometrial stromal adenocarcinoma, leiomyosarcoma; hExcludes those where morphology was unknown. CI, confidence interval; FIGO, International Federation of Gynaecology and Obstetrics; HR, hazard ratio; N, number.
